cardiovascular benefits of glp 1 agonists Frontiers GLP-1 receptor agonists: The cardiovascular

[PubMed] [Google Scholar] 31.Ussher JR, Drucker DJ

Its availability under multiple branded formulations further strengthens patient adoption and market leadership

Durinx C, Lambeir AM, Ne Bosmans E, Falmagne JB, Berghmans R, Haemers A, et al

NPs play a key role in addressing these barriers, advocating for patients, and promoting informed, stigma-free discussions that support safe and equitable use

Additionally, the neuroprotective effects of GLP1RAs have been shown to be achieved through multiple mechanisms

Conclusions Evidence accrued so far suggest that GLP-1RA could exert a modest renal benefit alongside CV protection, justifying its place as second-line drug in patients with T2D and CKD not achieving glycemic control with SGLT-2i and metformin according to KDIGO guidelines [87]